IDH1 and cancer: Intriguingly, we found that NAD+ levels are not altered in IDH1 mutated astrocytes [17], indicating successful compensatory mechanisms in those cells and, therefore, potentially limiting the vulnerability of cancer cells to NAD+ synthesis inhibition.